Having trouble viewing this email? View in your browser.
ESCMID Logo

29 January 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ESCMID Postgraduate Course on (Re-)merging Arboviruses – Ljubljana, Slovenia

Kick off your academic year with the first ESCMID Postgraduate Education Course in Ljubljana, Slovenia, 19-21 March 2019. Registrations are available online, and registrations include all course materials and 2 nights of accommodation in Ljubljana.

Find out more here

› Read more
OPEN CALLS | APPLICATIONS

Registration for ECCMID 2019

ECCMID is approaching soon in Amsterdam!

Registrations are available at a reduced rate for ESCMID members on the official website.

Make sure you use our official website to book your hotels to get the best rates.

› Read more

CMI Highlight: A Novel Framework to Compare the Effectiveness of β-lactamase Inhibitors against Extended-Spectrum β-lactamase-producing Enterobacteriaceae

Habodakpi et al., highlight a new practical approach to compare the performance of different inhibitors based on efficacy score when associated to a specific β-lactam.
Extended-spectrum β-lactamases (ESBLs) present a serious challenge in the treatment of Gram-negative bacterial infections. ESBLs mediate resistance to most β-lactams, which may be reversed with the addition of an active β-lactamase inhibitor (such as tazobactam, relebactam and avibactam). However, various ESBLs may exhibit different susceptibilities to these inhibitors, which could impact efficacy. We proposed a framework for comparing efficacy of these inhibitors when combined with the same β-lactam.
Three clinical isolates of K. pneumoniae harbouring CTX-M-15 and one E. coli isolate with SHV-12 were examined. Piperacillin minimum inhibitory concentrations (MICs) were determined by broth dilution using escalating concentrations of tazobactam, relebactam and avibactam. The resulting MICs were characterized as response to inhibitor concentrations using an inhibitory sigmoid Emax model. Using the best-fit parameter values, the model was conditioned with fluctuating inhibitor concentrations to simulate instantaneous MICi profiles for each isolate-inhibitor pair. Using a simulated exposure of 4 g piperacillin every 8 h, %fT>MICi was estimated for each piperacillin/inhibitor combination. A hollowfibre infection model was subsequently used to validate the predicted effectiveness of selected combinations.
In all scenarios, piperacillin MIC reductions were well characterized with increasing inhibitor concentrations. As predicted by %fT>MICi, combining piperacillin with avibactam (61.4 – 73.6%) was found to be superior to tazobactam (13.5 – 44.5%) for suppressing bacterial growth over time.

This platform may be used clinically to identify the optimal pairing of various β-lactams and β-lactamase inhibitors for individual isolates producing ESBLs.

› Read more
 

Applications for the ESCMID funded observership at the Mayo Clinic in Rochester (USA) are accepted until 31 January 2019 12:00 CET

Did you know that the call for ESCMID Funded Observership at the Mayo Clinic is currently open? We hope you take this opportunity to apply for this unique opportunity by Thursday, 31 January 2019 12:00 (CET) by using this link. There you will also find more information and instructions on how to start the application process.
As the deadline is coming closer, make sure to get your application to us as soon as possible. Don’t forget to pay attention to the criteria and ensure you have all the necessary documents to include in your application.
In case of questions, please contact: observership@escmid.org

The next call for funded observerships will be announced in Spring 2019.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.